LOXAPAC IM 50 MG
LOXAPINE (LOXAPINE HYDROCHLORIDE) : 50 MG · DIN 02169991 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is LOXAPAC IM?
LOXAPAC IM 50 MG contains LOXAPINE (LOXAPINE HYDROCHLORIDE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02169991, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 06-Oct-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LOXAPAC IM used for?
LOXAPAC IM (loxapine hydrochloride injection) is indicated in the management of the manifestations of schizophrenia. LOXAPAC IM is not indicated in elderly patients with dementia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02169991 |
|---|---|
| Brand name | LOXAPAC IM |
| Generic / active ingredient | LOXAPINE (LOXAPINE HYDROCHLORIDE) : 50 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 50 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | N05AH01 LOXAPINE |
| AHFS class | 28:16.08.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Oct-2005 |
| Original market date | 1997-06-13 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code N05AH01 LOXAPINE. 4 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| XYLAC | 10 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230838 |
| XYLAC | 2.5 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02242868 |
| XYLAC | 25 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230839 |
| APO-LOXAPINE | 10 MG | TABLET | APOTEX INC | APPROVED | DIN 02237652 |
| APO-LOXAPINE | 25 MG | TABLET | APOTEX INC | APPROVED | DIN 02237653 |
| APO-LOXAPINE | 5 MG | TABLET | APOTEX INC | APPROVED | DIN 02237651 |
| APO-LOXAPINE | 50 MG | TABLET | APOTEX INC | APPROVED | DIN 02237654 |
| DOM-LOXAPINE TABLETS 10MG | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239919 |
| DOM-LOXAPINE TABLETS 25MG | 25 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239920 |
| DOM-LOXAPINE TABLETS 50MG | 50 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239921 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.